Prof. John G. Gribben, MD, DSc - Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care With Groundbreaking Treatment
Go online to PeerView.com/NMB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The current chronic lymphocytic leukemia (CLL) management tool kit is expanding to include covalent and non-covalent BTK inhibitors, BCL-2 inhibitors, chemo-sparing combinations, and cellular therapies—are you prepared for this challenging and exciting new era in care? This “Seminars & Tumor Board” activity, adapted from our recent live event preceding the 64th ASH Annual Meeting and Exposition, can prepare you to adapt your practice through expert-led, case-based discussion with mini seminars designed to illustrate how fully integrating cutting-edge treatments can improve care in different and often challenging treatment settings. This program also features important resources from our collaborative partner, the CLL Society, that can be used to engage with your CLL patients during disease management. Upon completion of this activity, participants should be better able to: Cite the current evidence from pivotal clinical trials, head-to-head comparisons, and practice guidelines supporting the use of targeted and other novel therapies in CLL, including safety, efficacy, and selectivity differences; Select personalized frontline regimens with targeted therapies as single agents or as part of combination regimens for patients with TN CLL based on prognostic information, the presence of comorbidities, and safety considerations; Develop appropriate sequential and combinatorial treatment plans with targeted agents and cellular therapies for patients with therapeutic intolerance and/or R/R CLL; and Manage unique safety considerations associated with the use of targeted agents or other novel therapies in the CLL setting.